CN108743562A - 用于纳米聚合物基核酸递送的组合物和方法 - Google Patents

用于纳米聚合物基核酸递送的组合物和方法 Download PDF

Info

Publication number
CN108743562A
CN108743562A CN201810672707.5A CN201810672707A CN108743562A CN 108743562 A CN108743562 A CN 108743562A CN 201810672707 A CN201810672707 A CN 201810672707A CN 108743562 A CN108743562 A CN 108743562A
Authority
CN
China
Prior art keywords
nucleic acid
poly
glcnac
composition
deacetylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810672707.5A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·N·沃纳吉斯
玛丽娜·V·德姆契瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Polymer Technologies Inc
Original Assignee
Marine Polymer Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Technologies Inc filed Critical Marine Polymer Technologies Inc
Publication of CN108743562A publication Critical patent/CN108743562A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201810672707.5A 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法 Pending CN108743562A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US61/410,863 2010-11-06
US41135810P 2010-11-08 2010-11-08
US61/411,358 2010-11-08
CN2011800636609A CN103282024A (zh) 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800636609A Division CN103282024A (zh) 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法

Publications (1)

Publication Number Publication Date
CN108743562A true CN108743562A (zh) 2018-11-06

Family

ID=46025153

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810672707.5A Pending CN108743562A (zh) 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法
CN2011800636609A Pending CN103282024A (zh) 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011800636609A Pending CN103282024A (zh) 2010-11-06 2011-11-07 用于纳米聚合物基核酸递送的组合物和方法

Country Status (10)

Country Link
US (3) US20130287853A1 (https=)
EP (1) EP2635261B1 (https=)
JP (2) JP6029591B2 (https=)
CN (2) CN108743562A (https=)
AU (3) AU2011323078B2 (https=)
CA (1) CA2816999A1 (https=)
ES (1) ES2763432T3 (https=)
IL (1) IL226170B (https=)
MX (1) MX358050B (https=)
WO (1) WO2012061803A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
WO2011130646A1 (en) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
WO2012061803A2 (en) * 2010-11-06 2012-05-10 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery
NZ732118A (en) 2011-04-15 2018-11-30 Marine Polymer Tech Inc Treatment of disease with poly-n-acetylglucosamine nanofibers
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
CA2487564A1 (en) * 2004-11-12 2006-05-12 Valorisation Recherche Hscm Folic acid-chitosan-dna nanoparticles
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2008039390A2 (en) * 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
KR20090108723A (ko) * 2007-01-31 2009-10-16 알러간, 인코포레이티드 안 약물 송달을 위한 신규한 생체적합물질 및 이의 제조방법 및 용도
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
WO2011140638A1 (en) * 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
WO2012061803A2 (en) * 2010-11-06 2012-05-10 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王晓波: "《药物运释系统》", 31 August 2007 *

Also Published As

Publication number Publication date
IL226170B (en) 2018-11-29
EP2635261A4 (en) 2014-09-17
JP6029591B2 (ja) 2016-11-24
EP2635261A2 (en) 2013-09-11
JP2014500250A (ja) 2014-01-09
AU2013203247A1 (en) 2013-05-09
WO2012061803A2 (en) 2012-05-10
AU2011323078B2 (en) 2016-04-14
US20130287853A1 (en) 2013-10-31
EP2635261B1 (en) 2019-10-23
WO2012061803A3 (en) 2012-08-16
IL226170A0 (en) 2013-07-31
MX2013005016A (es) 2014-03-12
MX358050B (es) 2018-08-03
AU2011323078A1 (en) 2013-05-02
ES2763432T3 (es) 2020-05-28
AU2016201640A1 (en) 2016-04-07
CN103282024A (zh) 2013-09-04
US20230157971A1 (en) 2023-05-25
CA2816999A1 (en) 2012-05-10
US20170128382A1 (en) 2017-05-11
JP2016164181A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
US20230157971A1 (en) Compositions and methods for nanopolymer-based nucleic acid delivery
Lim et al. Engineered nanodelivery systems to improve DNA vaccine technologies
Yang et al. Recent advances in lipid nanoparticles for delivery of mRNA
Cai et al. Cationic polymers as transfection reagents for nucleic acid delivery
Jin et al. Nanoparticle‐mediated delivery of inhaled immunotherapeutics for treating lung metastasis
Henderson et al. Leveraging biological buffers for efficient messenger RNA delivery via lipid nanoparticles
Shin et al. COVID-19 vaccine development and a potential nanomaterial path forward
Hettinga et al. Vaccination into the dermal compartment: techniques, challenges, and prospects
Tang et al. Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Mao et al. Stimuli-responsive polymeric nanovaccines toward next-generation immunotherapy
Gholap et al. Harnessing nanovaccines for effective immunization─ a special concern on COVID-19: facts, fidelity, and future prospective
Baptista et al. mRNA, a Revolution in Biomedicine
Czapar et al. Plant viruses and bacteriophages for drug delivery in medicine and biotechnology
Rodríguez-Gascón et al. Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles
Zhao et al. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles
Saboo et al. Optimized formulation of a thermostable spray-dried virus-like particle vaccine against human papillomavirus
Wu et al. Novel thermal-sensitive hydrogel enhances both humoral and cell-mediated immune responses by intranasal vaccine delivery
KR102432434B1 (ko) Rna 투여용 제형
Zhang et al. Lipid Nanoparticle-based delivery System─ a competing place for mRNA vaccines
Niculescu et al. New applications of lipid and polymer-based nanoparticles for nucleic acids delivery
Xu et al. RNA replicon delivery via lipid-complexed PRINT protein particles
Finocchio et al. Recent developments in gene therapy for neovascular age-related macular degeneration: A review
Knight et al. Engineering vaccines for tissue‐resident memory T cells
Shao et al. Programming of in situ tumor vaccines via supramolecular nanodrug/hydrogel composite and deformable nanoadjuvant for cancer immunotherapy
Karan et al. In vivo delivery of spherical and cylindrical in vitro reconstituted virus-like particles containing the same self-amplifying mRNA

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181106

WD01 Invention patent application deemed withdrawn after publication